TG Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.

CEO

Michael Sean Weiss

CEOMichael Sean Weiss

Employees

338

Employees338

Headquarters

Morrisville, North Carolina

HeadquartersMorrisville, North Carolina

Founded

1993

Founded1993

Employees

338

Employees338

TGTX Key Statistics

Market cap

4.24B

Market cap4.24B

Price-Earnings ratio

74.53

Price-Earnings ratio74.53

Dividend yield

—

Dividend yield—

Average volume

3.60M

Average volume3.60M

High today

$28.14

High today$28.14

Low today

$26.52

Low today$26.52

Open price

$27.50

Open price$27.50

Volume

4.80M

Volume4.80M

52 Week high

$46.48

52 Week high$46.48

52 Week low

$19.45

52 Week low$19.45

TGTX News

Seeking Alpha 5d

TG Therapeutics misses top-line and bottom-line estimates; raises FY25 outlook

Earnings News TG Therapeutics misses top-line and bottom-line estimates; raises FY25 outlook Aug. 04, 2025 7:03 AM ET TG Therapeutics, Inc. (TGTX) Stock By: Meg...

Analyst ratings

75%

of 8 ratings

Buy

75%

Hold

12.5%

Sell

12.5%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.